Difluoromescaline

Pharmaceutical compound From Wikipedia, the free encyclopedia

Difluoromescaline (DFM), also known as 4-difluoromethoxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3] It is a difluorinated derivative of mescaline.[1][2][3]

Other namesDFM; 4-Difluoromethoxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-difluoromethoxyphenethylamine
ATC code
  • None
Quick facts Clinical data, Other names ...
Difluoromescaline
Clinical data
Other namesDFM; 4-Difluoromethoxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-difluoromethoxyphenethylamine
Routes of
administration
Oral[1][2][3]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action12–18 hours[1][2][3]
Identifiers
  • 2-[4-(difluoromethoxy)-3,5-dimethoxyphenyl]ethanamine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC11H15F2NO3
Molar mass247.242 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OC(F)F)OC)CCN
  • InChI=1S/C11H15F2NO3/c1-15-8-5-7(3-4-14)6-9(16-2)10(8)17-11(12)13/h5-6,11H,3-4,14H2,1-2H3
  • Key:MMARNDCKXDBJES-UHFFFAOYSA-N
Close

The drug's dose range is 50 to 100 mg orally and its duration is 12 to 18 hours.[1][2][3] It is about 3- or 4-fold more potent than mescaline and has a longer duration in comparison.[1][2] The drug is said to produce strong psychedelic effects.[3]

Difluoromescaline interacts with serotonin receptors and acts as a low-potency full agonist of the serotonin 5-HT2A receptor.[1][2][3]

It was first described in the scientific literature by Daniel Trachsel in 2012.[2][1][3] The drug's pharmacology was studied in more detail in 2021.[3] It is not a controlled substance in Canada as of 2025.[4]

See also

References

Related Articles

Wikiwand AI